Ro-3306, a CDK1-selective inhibitor with 10-fold greater selectivity over CDK2 and 50-fold over CDK4 [42] (also reported to decrease BCL-2 protein in AML [43]) did not correlate with alvocidib. This evidence concerns the gene CDK2 and acute myeloid leukemia.